Human Growth Hormone in Management of Poor Responders (the Light Study)

Investigators: Prof Robert Norman (1), A/Prof Luk Rombauts (2,3), Dr Gareth Weston (2,3), Caroline Motteram (2), Deborah de Guingand (1)

1 Robinson Institute, The University of Adelaide; 2Monash IVF, Clayton;  3Monash Dept Obstetrics and Gynaecology

The ability of oocytes to form structurally normal embryos that are able to implant has been related to the concentration of hormones in ovarian follicular fluid. Growth hormone (GH) levels in blood have shown the most consistent relationship with parameters of embryo quality, with higher concentrations associated with rapid cleavage, better cleaving embryo morphology and higher embryo implantation potential. The rationale for recombinant Growth Hormone (r-GH) use is that it may potentiate the effect of the gonadotrophin treatment used in IVF. GH is reported to modulate the action of FSH on granulosa cells by up-regulating the local synthesis of insulin-like growth factor-I (IGF-I). This amplifies the effect of gonadotrophin action at the level of both the granulosa and theca cell. This clinical trial aimed to determine the effect of r-GH co-stimulation on live birth rates in poor responders undergoing an IVF/ICSI cycle.

Recruitment for this project has now completed and the preliminary results were presented at the Fertility Society of Australia scientific meeting in September 2015. The results are currently being prepared for publication.


  • This field is for validation purposes and should be left unchanged.
  • This field is for validation purposes and should be left unchanged.